Difference between revisions of "Cabazitaxel (Jevtana)"
Jump to navigation
Jump to search
m (→References) |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization, inhibiting interphase/mitosis processes.<ref name="insert">[http://products.sanofi.us/jevtana/jevtana.pdf Cabazitaxel (Jevtana) package insert]</ref><ref>[[Media:Cabazitaxel.pdf | Cabazitaxel (Jevtana) package insert (locally hosted backup)]]</ref><ref>[http://www.jevtana.com/ Jevtana manufacturer's website]</ref> | Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization, inhibiting interphase/mitosis processes.<ref name="insert">[http://products.sanofi.us/jevtana/jevtana.pdf Cabazitaxel (Jevtana) package insert]</ref><ref>[[Media:Cabazitaxel.pdf | Cabazitaxel (Jevtana) package insert (locally hosted backup)]]</ref><ref>[http://www.jevtana.com/ Jevtana manufacturer's website]</ref> | ||
| Line 12: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://products.sanofi.us/jevtana/jevtana.pdf | + | *[http://products.sanofi.us/jevtana/jevtana.pdf Cabazitaxel (Jevtana) package insert]<ref name="insert"></ref> |
| − | *[http://chemocare.com/chemotherapy/drug-info/ | + | *[http://chemocare.com/chemotherapy/drug-info/cabazitaxel.aspx Cabazitaxel (Jevtana) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cabazitaxel.aspx Cabazitaxel (Jevtana) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/cabazitaxel-patient-drug-information Cabazitaxel (Jevtana) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cabazitaxel-patient-drug-information Cabazitaxel (Jevtana) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/cabazitaxel-patient-drug-information Cabazitaxel (Jevtana) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cabazitaxel-patient-drug-information Cabazitaxel (Jevtana) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 6/17/2010: Initial FDA approval "in combination with [[Prednisone (Sterapred) | prednisone]] for treatment of patients with hormone-refractory metastatic [[Prostate cancer | prostate cancer]] previously treated with a [[Docetaxel (Taxotere) | docetaxel]]-containing treatment regimen." | * 6/17/2010: Initial FDA approval "in combination with [[Prednisone (Sterapred) | prednisone]] for treatment of patients with hormone-refractory metastatic [[Prostate cancer | prostate cancer]] previously treated with a [[Docetaxel (Taxotere) | docetaxel]]-containing treatment regimen." | ||
| + | |||
| + | ==Also known as== | ||
| + | XRP6258, TXD258, or RPR116258A. | ||
==References== | ==References== | ||
Revision as of 22:03, 2 April 2016
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization, inhibiting interphase/mitosis processes.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cabazitaxel (Jevtana) package insert[1]
- Cabazitaxel (Jevtana) patient drug information (Chemocare)[4]
- Cabazitaxel (Jevtana) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 6/17/2010: Initial FDA approval "in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen."
Also known as
XRP6258, TXD258, or RPR116258A.